Screening and Treatment for Alcohol, Tobacco and Opioid Use Disorders: A Survey of Family Physicians Across Ontario
Overview
Affiliations
Introduction: As a primary point of contact within the health care system, family physicians are able to play a vital role in identifying individuals with substance use disorders and connecting them to the appropriate treatment. However, there is very little data available on whether family physicians are actively screening for and treating substance use disorders. The objective of the current survey was to assess whether family physicians in Ontario are screening for alcohol, opioid and tobacco use disorders, using validated tools and providing treatment.
Methods: An online survey consisting of a series of 38 primarily close-ended questions was circulated to family physicians in Ontario. Rates of screening for alcohol, opioid and tobacco dependence, use of validated tools for screening, providing treatment for dependent individuals and the current barriers to the prescription of pharmacotherapies for these drug dependences were assessed.
Results: The use of validated screening tools was limited for all three substances. Screening by family physicians for the substance use disorders among adolescents was much lower than screening among adults. Pharmacotherapy was more commonly used as an intervention for tobacco dependence than for alcohol and opioid dependence. This was explained by the lack of knowledge among family physicians on the pharmacotherapies for alcohol and opioid dependence.
Conclusions: Findings from the current study suggest there is a need for family physicians to integrate screening for substance use disorders using validated tools into their standard medical practice. Furthermore, there is a need for increased knowledge on pharmacotherapies for alcohol and opioid use disorders. It is important to note that the low response rate is a major limitation to this study. One possible reason for this low response rate may be a lack of interest and awareness among family physicians on the importance of screening and treatment of substance use disorders in Ontario.
Fouillen K, Clement C, Aous E, Le Goff D, Le Reste J, Guillou-Landreat M Drug Alcohol Rev. 2025; 44(2):667-680.
PMID: 39888144 PMC: 11814361. DOI: 10.1111/dar.14002.
Physician Reluctance to Intervene in Addiction: A Systematic Review.
Campopiano von Klimo M, Nolan L, Corbin M, Farinelli L, Pytell J, Simon C JAMA Netw Open. 2024; 7(7):e2420837.
PMID: 39018077 PMC: 11255913. DOI: 10.1001/jamanetworkopen.2024.20837.
Recommending COVID-19 Vaccines to Patients: Practice and Concerns of Frontline Family Doctors.
Poon P, Zhou W, Chan D, Kwok K, Wong S Vaccines (Basel). 2021; 9(11).
PMID: 34835250 PMC: 8624411. DOI: 10.3390/vaccines9111319.
Minian N, Noormohamed A, Lingam M, Zawertailo L, Le Foll B, Rehm J Addict Sci Clin Pract. 2021; 16(1):17.
PMID: 33726843 PMC: 7968293. DOI: 10.1186/s13722-021-00225-x.
Minian N, Lingam M, Moineddin R, Thorpe K, Veldhuizen S, Dragonetti R JMIR Res Protoc. 2020; 9(9):e19157.
PMID: 32990250 PMC: 7556369. DOI: 10.2196/19157.